Clinical Coagulation, Malmö
501 – 600 of 629
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2006
-
Mark
Liposuction in Dercum's disease.
2006) p.516-518(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
The next generation of hemophilia treatment specialists
(
- Contribution to journal › Article
- 2005
-
Mark
Quiescence of hematopoietic stem cells and maintenance of the stem cell pool is not dependent on TGF-beta signaling in vivo.
(
- Contribution to journal › Article
-
Mark
Long-term prophylaxis in von Willebrand disease
(
- Contribution to journal › Article
-
Mark
Recurrence Rate After a First Venous Thrombosis in Patients With Familial Thrombophilia.
(
- Contribution to journal › Article
-
Mark
Protein C levels can be forecasted by global haemostatic tests in critically ill patients and predict long-term survival.
(
- Contribution to journal › Article
-
Mark
Genetic analysis of 31 Swedish type 1 von Willebrand disease families reveals incomplete linkage to the von Willebrand factor gene and a high frequency of a certain disease haplotype.
(
- Contribution to journal › Article
-
Mark
APC-PCI complex concentration is higher in patients with previous venous thromboembolism with Factor V Leiden.
(
- Contribution to journal › Letter
-
Mark
Factor V Leiden and the prothrombin 20210A gene mutation and osteonecrosis of the knee.
(
- Contribution to journal › Article
-
Mark
Cost effectiveness of haemophilia treatment: a cross-national assessment.
(
- Contribution to journal › Article
-
Mark
Haemophilia Inhibitor Genetics Study - evaluation of a model for studies of complex diseases using linkage and association methods.
(
- Contribution to journal › Letter
-
Mark
Pharmacokinetic studies on Wilfactin((R)), a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods
(
- Contribution to journal › Article
-
Mark
The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A.
(
- Contribution to journal › Article
-
Mark
Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT)
(
- Contribution to journal › Article
-
Mark
Risk factors for venous thrombosis in Swedish children and adolescents.
(
- Contribution to journal › Article
-
Mark
Protein Z and protein Z-dependent protease inhibitor - Determinants of levels and risk of venous thrombosis
(
- Contribution to journal › Article
- 2004
-
Mark
Familial thrombophilia and lifetime risk of venous thrombosis
(
- Contribution to journal › Article
-
Mark
Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden.
(
- Contribution to journal › Article
-
Mark
Co-segregation of the PROS1 locus and protein S deficiency in families having no detectable mutations in PROS1.
(
- Contribution to journal › Article
-
Mark
Hereditary thrombophilia and fetal loss: a prospective follow-up study
(
- Contribution to journal › Article
-
Mark
Economic evaluation: what are we looking for and how do we get there?
(
- Contribution to journal › Article
-
Mark
Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study
(
- Contribution to journal › Article
-
Mark
A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia
(
- Contribution to journal › Article
-
Mark
Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A
(
- Contribution to journal › Article
-
Mark
Comparison between CoaguChek S- and Owren-type prothrombin time assay for monitoring anticoagulant therapy.
(
- Contribution to journal › Article
-
Mark
A pharmacokinetic and pharmacodynamic study of desmopressin: evaluating sex differences and the effect of pre-treatment with piroxicam, and further validation of an indirect response model.
(
- Contribution to journal › Article
-
Mark
Willingness to pay for on-demand and prophylactic treatment for severe haemophilia in Sweden.
(
- Contribution to journal › Article
-
Mark
Factor V leiden and prothrombin gene mutation: risk factors for osteonecrosis of the femoral head in adults.
(
- Contribution to journal › Article
-
Mark
Elective orthopedic surgery for hemophilia patients with inhibitors: New opportunities
(
- Contribution to journal › Article
- 2003
-
Mark
The pharmacokinetics of clotting factor therapy.
(
- Contribution to journal › Article
-
Mark
Monitoring the bioavailability of FEIBA with a thrombin generation assay
(
- Contribution to journal › Article
-
Mark
Experience with a new percutaneous port system, Percuseal(R), for intravenous injection in patients with haemophilia, von Willebrand disease and severe alpha1-antitrypsin deficiency.
(
- Contribution to journal › Article
-
Mark
When to start and when to stop primary prophylaxis in patients with severe haemophilia.
(
- Contribution to journal › Article
-
Mark
Prophylactic therapy for haemophilia: early experience.
(
- Contribution to journal › Article
-
Mark
On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome.
(
- Contribution to journal › Article
-
Mark
Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay
(
- Contribution to journal › Article
-
Mark
Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro.
(
- Contribution to journal › Article
-
Mark
Consensus perspectives on prophylactic therapy for haemophilia: summary statement.
(
- Contribution to journal › Letter
-
Mark
A Healthy Hemophilic Patient without Arthropathy: From Concept to Clinical Reality.
(
- Contribution to journal › Article
-
Mark
Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations: is it of clinical importance?
(
- Contribution to journal › Article
-
Mark
Elective orthopaedic surgery for inhibitor patients.
(
- Contribution to journal › Article
-
Mark
Risk of haemorrhagic stroke in patients with oral anticoagulation compared with the general population
(
- Contribution to journal › Article
-
Mark
Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human alpha(1)-antitrypsin.
(
- Contribution to journal › Article
-
Mark
Limited protective effect of the CCR5 Delta 32/CCR5 Delta 32 genotype on human immunodeficiency virus infection incidence in a cohort of patients with hemophilia and selection for genotypic X4 virus
(
- Contribution to journal › Article
- 2002
-
Mark
Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients
(
- Contribution to journal › Article
-
Mark
Unresolved issues in prophylaxis
(
- Contribution to journal › Article
-
Mark
Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans.
(
- Contribution to journal › Article
-
Mark
Clinical outcomes and resource utilization associated with haemophilia care in Europe
(
- Contribution to journal › Article
-
Mark
Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen
(
- Contribution to journal › Article
-
Mark
The prognostic value of global haemostatic tests in the intensive care unit setting.
(
- Contribution to journal › Article
-
Mark
Progress in haemophilic care: ethical issues.
(
- Contribution to journal › Article
-
Mark
Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors.
(
- Contribution to journal › Article
-
Mark
Multidisciplinär kurs i akutmedicin ger ST-läkare större säkerhet
(
- Contribution to journal › Article
-
Mark
Roper and rovent scintigraphic points in pulmonary embolism as a safe basis in out-patient tinzaparin therapy
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
- 2001
-
Mark
The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients
(
- Contribution to journal › Article
-
Mark
Anti- and procoagulant activities in factor VII-deficient subjects
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction: recombinant vs. human-derived product
(
- Contribution to journal › Article
-
Mark
An approach to study the viral safety of plasma-derived products in previously treated, non-infected patients
(
- Contribution to journal › Article
-
Mark
Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis
(
- Contribution to journal › Article
-
Mark
Clinical spectrum of hepatitis C-related liver disease and response to treatment with interferon and ribavirin in haemophilia or von Willebrand disease
(
- Contribution to journal › Article
-
Mark
Therapeutic choices for patients with hemophilia and high-titer inhibitors
(
- Contribution to journal › Article
-
Mark
The concern of viral safety in the treatment of hemophilia
(
- Contribution to journal › Article
-
Mark
Hormone replacement therapy in healthy postmenopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factors
(
- Contribution to journal › Article
-
Mark
The clinical importance of correctly diagnosing venous thrombosis
(
- Contribution to journal › Article
-
Mark
No increased risk of venous thrombosis in women taking tranexamic acid
(
- Contribution to journal › Letter
-
Mark
Symposium in memory of Professor Inga Marie Nilsson
(
- Contribution to journal › Published meeting abstract
-
Mark
Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia
(
- Contribution to journal › Scientific review
-
Mark
Byte från Prothromplex till Beriplex P/N som akut antidot mot warfarin
(
- Contribution to journal › Article
- 2000
-
Mark
NovoSeven in warfarin-treated patients
(
- Contribution to journal › Article
-
Mark
Correlation between different intensities of anti-vitamin K treatment and coagulation parameters
(
- Contribution to journal › Article
-
Mark
Effect kinetics of desmopressin-induced platelet retention in healthy volunteers treated with aspirin or placebo
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction and the treatment of hemophilia. Malmo protocol update
(
- Contribution to journal › Article
-
Mark
Använd hela "analyspaketet" vid utredning av trombospatienten! Och glöm inte släktingarna ...
(
- Contribution to journal › Article
-
Mark
The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies
(
- Contribution to journal › Article
-
Mark
Impact, diagnosis and treatment of von Willebrand disease
(
- Contribution to journal › Article
-
Mark
Replik: Behandlingstiden har effekter och bieffekter
(
- Contribution to journal › Article
-
Mark
Recombinant FVIIa in the treatment of warfarin bleeding
(
- Contribution to journal › Article
-
Mark
Molecular genetic analysis of severe protein C deficiency
(
- Contribution to journal › Article
-
Mark
Regimens of factor VIII administration--continuous infusion vs. bolus
(
- Contribution to journal › Article
-
Mark
The Malmo model for immune tolerance induction: impact of previous treatment on outcome
(
- Contribution to journal › Article
-
Mark
Inflammatory bowel disease promotes venous thrombosis earlier in life
(
- Contribution to journal › Article
- 1999
-
Mark
Changes in levels of factor VII and protein S after acute myocardial infarction: effects of low-dose warfarin
(
- Contribution to journal › Article
-
Mark
Progression of retinopathy after improved metabolic control in type 2 diabetic patients. Relation to IGF-1 and hemostatic variables
(
- Contribution to journal › Article
-
Mark
Centraliserad vård grundläggande i vårdprogram för blödarsjuka
(
- Contribution to journal › Article
-
Mark
Nya rön om behandling av djup ventrombos: Behandlingstidens längd föremål för internationella studier
(
- Contribution to journal › Article
-
Mark
Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized
(
- Contribution to journal › Article
-
Mark
Tolerance induction using the Malmo treatment model 1982-1995
(
- Contribution to journal › Article
-
Mark
Malmo International Brother Study (MIBS): an international survey of brother pairs with haemophilia
(
- Contribution to journal › Article
-
Mark
Factor V Q506 (resistance to activated protein C) and prognosis after acute coronary syndrome
(
- Contribution to journal › Article
-
Mark
Other ongoing rFVIII PUP studies
(
- Contribution to journal › Article
-
Mark
HELLP en livshotande graviditetskomplikation. Specifik koagulationsfaktorbehandling nu möjlig
(
- Contribution to journal › Article
-
Mark
Nytt system testar den mekaniska hjärtklaffen. Egenkontroll i hemmet av antivitamin K-terapin ger patienten större frihet
(
- Contribution to journal › Article
- 1998
-
Mark
Continuous infusion of factor IX concentrate to induce immune tolerance in two patients with haemophilia B
(
- Contribution to journal › Article
-
Mark
Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis
(
- Contribution to journal › Article
-
Mark
Immunoadsorption for removal of inhibitors: update on treatments in Malmo-Lund between 1980 and 1995
(
- Contribution to journal › Article
-
Mark
Major surgery seems not to influence HIV disease progression in haemophilia patients
(
- Contribution to journal › Article
-
Mark
Liposuction in Dercum's disease: impact on haemostatic factors associated with cardiovascular disease and insulin sensitivity.
(
- Contribution to journal › Article
-
Mark
Low recurrence rate after deep calf-vein thrombosis with 6 weeks of oral anticoagulation
(
- Contribution to journal › Article
-
Mark
The Malmo-Klaipeda WFH twinning programme: a comparative description of the haemophilia cohorts
(
- Contribution to journal › Scientific review
-
Mark
The A20210 allele of the prothrombin gene is frequently associated with the factor V Arg 506 to Gln mutation but not with protein S deficiency in thrombophilic families
(
- Contribution to journal › Letter